May 6th 2024
Disparities in health care systems around the world limit access to effective treatments for advanced breast cancer, especially for people in low- and middle-income countries and marginalized communities. Stronger health systems and social education efforts are necessary to improve outcomes for all patients.
Wide Variation Seen in County-Level Breast Cancer Mortality Linked to SDOH
November 4th 2023Data from 2176 US counties link obesity and higher breast cancer mortality, while also showing varying degrees of association between mortality and access to healthy lifestyle options per social determinants of health (SDOH).
Read More
Racial, Ethnic Disparities Seen in Breast Cancer Survival, Even Among Clinical Trial Participants
October 25th 2023It is critical to understand the role race and ethnicity play in survival for patients with early-stage breast cancer (eBC), as well as explore potential interventions to close these gaps.
Read More
Opt-In vs Opt-Out Patient Outreach Programs Yield Similar Mammography Completion Rates
October 21st 2023No differences in mammography completion were observed between an automated opt-out vs an opt-in patient outreach program for breast cancer screening, according to a randomized controlled trial. However, differences in administration burden between programs could lead clinics to prefer one over the other.
Read More
Contributor: Advancing Breast Cancer Treatment—The Role of Clinical Trials and the Path Ahead
October 11th 2023Clinical studies have transformed how breast cancer is prevented, identified, and treated. Successful clinical trials improve patient outcomes, so trial administrators must ensure participants receive appropriate support at trial enrollment.
Read More
FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer
October 6th 2023The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a poly (ADP-ribose) polymerase inhibitor.
Read More
Dato-Dxd Shows Survival Improvements in HR+/HER2– Breast Cancer
September 29th 2023The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor–positive (HR+), HER2-negative (HER2–) breast cancer were treated with datopotamab deruxtecan.
Read More
Breast Cancer Risk Linked to Air Pollution Exposure
September 22nd 2023Data from 6 states—California, Florida, Louisiana, New Jersey, North Carolina, and Pennsylvania—and 2 metropolitan areas—Atlanta, Georgia, and Detroit, Michigan—collected through the National Institutes of Health–AARP Diet and Health Study were used for the investigation.
Read More
Diet and Exercise Intervention Associated With Better pCR in TNBC or HR+, HER2– BC
September 16th 2023Despite seeming to elicit more pathological complete responses (pCRs) in patients with hormone receptor–positive (HR+), HER2-negative triple-negative breast cancer (BC) receiving neoadjuvant chemotherapy, diet and exercise did not affect relative dose intensity.
Read More
Regional Disparities Remain in Breast Reconstruction for Patients With Breast Cancer
September 15th 2023While regional variations were identified in rates of breast reconstruction, complications, and cost for patients with breast cancer, these differences did not seem to be associated with any implicit bias.
Read More
Condensed Proton Therapy Schedule Shows Promise for Patients With Breast Cancer
September 8th 2023New research suggests conventional fractionated and hypofractionated proton postmastectomy radiotherapy (PMRT) yield similar tolerability and complication rates for patients following mastectomy.
Read More
Using Genomic Assays to Learn Which Patients With Breast Cancer Could Get Less Treatment
September 5th 2023Coverage from the July 25, 2023, session of the Institute for Value-Based Medicine®, presented by The American Journal of Managed Care® in partnership with Emory's Winship Cancer Institute.
Read More
FDA Expands Abemaciclib Indication in HR+/HER2–, Node+, High-Risk Breast Cancer
March 7th 2023The FDA approved an expanded indication for abemaciclib (Verzenio) in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)–positive, HER2-negative, node-positive, early breast cancer that is at a high risk of recurrence.
Read More
FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer
January 27th 2023The FDA has approved elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.
Read More
Trastuzumab Deruxtecan Wins Rapid Approval for HER2-Low Breast Cancer
August 6th 2022The approval came exactly 2 months after results from the landmark DESTINY-Breast04 trial showed that the antibody drug conjugate reduced the risk of disease progression or death by 50% compared with chemotherapy for HER2-low patients with both hormone receptor (HR)–positive and HR-negative disease.
Read More
Dr Debra Patt on Capturing the HER2-Low Population
July 24th 2022Understanding that patients who are HER2-low are different from patients who are HER2-positive and -negative means having the right way to evaluate and identify these patients, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.
Watch
Dr Hope S. Rugo Discusses Clinical Trial Minority Recruitment, PALOMA-2 Findings
June 16th 2022Hope S. Rugo, MD, FASCO, is professor of medicine and the director of the Breast Oncology and Clinical Trials Education program at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. She discusses her experience with palbociclib and letrozole in advanced breast cancer.
Watch